ReviewCell biochemistry and biophysics2026
Mesenchymal Stem Cell-Based Therapies: Challenges and Enhancement Strategies.
Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Adiponectin preserves follicles through ADIPOR1/ADIPOR2-driven fatty acid metabolism.Molecular metabolism · 2026Article
- PPARβ/δ priming enhances mesenchymal stromal cell anti-apoptotic properties on chondrocytes via ANGPTL4 and improves their therapeutic effects in osteoarthritis.Stem cells translational medicine · 2026Article
- Therapeutic Impact of Mitochondrial Transplants for Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Bioprinting in Tissue Repair and Its ENT Applications.Polymers · 2026Review
- The progress and challenges of mesenchymal stromal cell-based therapy for diabetes and its complications.Biological research · 2026Review
- Mesenchymal Stromal/Stem Cells (MSCs) in Cancer Therapy: Advanced Therapeutic Strategies Towards Future Clinical Translation.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) are popular therapeutic candidates among researchers. MSCs have been used in many preclinical and clinical studies and their safety profile and efficacy are well documented. Despite the many advantages of using MSCs in research and treatment, researchers face several challenges and limitations in MSC cell-based therapies. Over the years, many studies have explored enhancement strategies to improve the therapeutic effects of MSCs. These enhancement strategies range from generating MSCs from alternative sources, genetically modifying MSCs and priming or preconditioning MSCs in specific culture conditions before applying MSCs in treatment. On the other hand, cell-free therapies are emerging and gaining popularity in recent years. This review gives an overview of the therapeutic properties of MSCs and provides an in-depth discussion on the challenges and enhancement strategies in MSC cell-based therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.